DexCom — Jan 7, 2026 release

This outlook considers sensor volume growth driven by increasing CGM awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics. In addition, Dexcom currently estimates 2026 Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin to be at the following levels: – Non-GAAP Gross Profit Margin of approximately 63 – 64% – Non-GAAP Operating Margin of approximately 22 – 23% Fourth Quarter 2025 Financial Results Conference Call Dexcom will report its audited full fourth quarter and fiscal 2025 financial results on Thursday, February 12, 2026 after the close of market. Management is currently scheduled to host a conference call at 4:30 p.m. (Eastern Time) that day. More details will be provided later. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com. Category: IR Statement Regarding Use of Non-GAAP Financial Measures This press release includes non-GAAP financial measures. We have not reconciled our Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance for fiscal years 2025 and 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. A